Citigroup Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $106.00

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price boosted by Citigroup from $88.00 to $106.00 in a report published on Monday morning, The Fly reports. Several other research firms have also commented on APLS. HC Wainwright increased their price target on shares of Apellis Pharmaceuticals from $87.00 to $100.00 in a research report […]

Related Keywords

United States ,America ,Adamj Townsend ,Cedric Francois ,Candace Rose Depp ,Robertw Baird ,Pascal Deschatelets ,Securities Exchange Commission ,Apellis Pharmaceuticals Company Profile ,Vanguard Group Inc ,Institutional Trading Of Apellis Pharmaceuticals ,News Ratings For Apellis Pharmaceuticals Daily ,Apellis Pharmaceuticals ,Needham Company ,T Rowe Price Investment Management Inc ,Citigroup ,Apellis Pharmaceuticals Inc ,Blackrock Inc ,Apellis Pharmaceuticals Stock Down ,Analyst Recommendations For Apellis Pharmaceuticals ,Avoro Capital Advisors ,Get Rating ,Moderate Buy ,Pharmaceuticals Stock Down ,Exchange Commission ,Capital Advisors ,Rowe Price Investment Management ,State Street Corp ,Street Corp ,Alec Machiels ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Boost Price Target ,Citigroup Inc ,